Global Acute Coronary Syndrome Therapeutics Market to Reach US$19 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Acute Coronary Syndrome market. The world market for Acute Coronary Syndrome (ACS) is projected to reach US$19 billion by the year 2015. This is primarily driven by growing instances of prevalence and incidences in the developed markets of the US and Europe, as well as growing demand for ACS drugs in the emerging markets of Brazil, China, India, Mexico, Russia, among others.

Acute Coronary Syndrome: A Global Market Report

The world Acute Coronary Syndrome (ACS) therapeutics market is dominated by industrialized economies. Sales of ACS drugs are escalating in emerging economies of Brazil, China, India, Mexico, Russia, South Korea, and Turkey. Improving primary care that is extending access of both branded and generic drugs, even to rural areas, as well as the growing uptake of private health insurance are defining trends in these regional markets. The ACS drugs market will continue to benefit from developing economies where the healthcare focus is moving away from combating infectious diseases to controlling and managing serious illnesses, as stated by the new market research report on acute coronary syndrome market.

Among the ACS drug categories, slow growth is particularly evident in antihyperlipidemics, which is witnessing contraction in value sales for statins such as Lipitor, as they face threat of genericization. In contrast is the performance of antithrombotics category where sales are robust and are being driven by Plavix and Lovenox. Though both face genericization, a powerful antithrombosis drug development pipeline featuring GPIIb/IIIa inhibitors, Factor Xa inhibitors and oral direct thrombin inhibitors, exhibits promising results for this category. Despite a strong pipeline, any new product is unlikely to have potential to replace statins, ensuring that statins will continue to be the drug of choice for lowering cholesterol. As several branded products are lined to lose patent protection between 2010 and 2012, cheaper generics will become more commonplace affecting dollar sales growth.

Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Inverness Medical Innovations, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi-Aventis SA, Siemens Healthcare Diagnostics, Inc., and Takeda Pharmaceutical Company Limited, among others.

The report titled "Acute Coronary Syndrome: A Global Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, product overview, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and analytics in terms of value sales for the global market.

For more details about this comprehensive market research report, please visit -
http://www.strategyr.com/Acute_Coronary_Syndrome_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website